Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

hich should not be given to healthy volunteers, this evaluation is being done in previously untreated elderly patients with de novo poor-risk AML who receive Cloretazine(R) (VNP40101M) therapy.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)... July 30, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin ... non-exclusive Development Agreements with Dexcom, Inc. to allow ... with the Dexcom G5 and G6 continuous glucose ... generation pump platform with Dexcom,s future CGM systems ...
(Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ --,NicOx S.A. ... phase 2a,study for NCX 1000, which is covered ... A preliminary analysis of 11 patients,from this proof-of-concept ... NCX 1000 but did not demonstrate the efficacy,required ...
... 2007--Sciele Pharma, Inc.,(NASDAQ:SCRX) today announced the successful completion ... formulation. The study,results showed that the new Sular ... new Sular formulation,utilizes SkyePharma's (LSE:SKP) patented Geomatrix technology,which ... Sular for each of its,current doses. , The ...
Cached Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 2Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 4
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... The condition ... among both men and women often causing pain and discomfort. Those who spend a ... circulatory problem, and Northeast Houston Vein Center is doing what it can to create ...
(Date:8/1/2015)... ... 01, 2015 , ... On Tuesday, July 28th, Symantec released a security industry ... been behind the attack on Anthem Inc. which resulted in one of the largest ... attacks and spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... magazine. What are the STASH awards? The Significant Technological Achievements in Secretive ... cannabis-cultivation community as well as tried-and-true products that have stood the test of ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... Ticket ... which is currently going on in Chicago at Grant Park. The festival will ... corner of North America to Chicago for the annual Lollapalooza. This unique and ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 , ... ... CoolSculpting , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator ... FDA in January 2014 for treating the outer thighs. The original applicator required ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... PARI,s Hydrate, a novel,medical humidifier, was awarded a ... 18, 2007. PARI Innovative Manufacturers, a leading,manufacturer of ... the way gases are heated and humidified with ... give clinicians greater control,of patient comfort. The ...
... local extinctions in a majority of species while enhancing ... the University of Illinois shows that parasites can play ... fragmented forests. This is the first study to look ... parasites on animals already stressed by disturbances to their ...
... Verathon Medical(R), the global,leader in the ... is pleased to announce that the European ... -- European Patent 1307131 B1 --,against a ... This,patent protects Verathon,s invention of its innovative, ...
... Public Schools in New York, New ... Jersey and Connecticut, ... rate monitors and fitness assessment technology, and a founding,member of the ... provide grant recipients in New York, New,Jersey and Connecticut with heart ...
... Community Urges SJHS to Agree to Fair Union Election ... and activist Ed Begley, Jr., will be among those ... St. Jude Medical,Center at a procession Saturday outside the ... workers seeking to form a union at SJHS hospitals ...
... Louis Sullivan, M.D., Former Secretary of HHS, Senator Norm ... Mark McClellan, M.D., Ph.D., and,members of the patient and ... the scientific evidence countering the United States Preventive, Services ... Screening, ARLINGTON, Va., Oct. 24 The Potomac,Institute ...
Cached Medicine News:Health News:PARI's Hydrate Wins Prestigious R&D 100 Award 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 3Health News:European Patent Office Upholds Verathon's IP Against Aircraft Medical Challenge 2Health News:Polar Joins Alliance to Combat Childhood Obesity 2Health News:Polar Joins Alliance to Combat Childhood Obesity 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 2Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 4Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 5
... standard in corneal diagnostics. Precise Display ... membrane, stroma, Bowman's membrane and epithelial ... Broad Applications in Surgery and Pathology. ... evaluation, endothelial cell analysis, haze detection, ...
... appearance of photo-aged skin, removes age spots ... and broken capillaries. This innovative new application ... pigmentary sun damage through a process called ... and the Nd:YAG Laser is optimized for ...
... affordable lenses available in a variety ... available in prescription powers for those ... "Plano" for those who don't. They ... technology. Incredibly comfortable, 10 fun, eye-catching ...
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: